{"id":343536,"date":"2026-11-11T10:53:16","date_gmt":"2026-11-11T05:23:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=343536"},"modified":"2026-11-11T10:53:16","modified_gmt":"2026-11-11T05:23:16","slug":"lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/","title":{"rendered":"Lupin Share Price: 18.9% CAGR in 3 Years as the Respiratory Specialist Stands Against Zydus and Sun Pharma"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Lupin_Share_Price_189_CAGR_in_3_Years_as_the_Respiratory_Specialist_Stands_Against_Zydus_and_Sun_Pharma\" title=\"Lupin Share Price: 18.9% CAGR in 3 Years as the Respiratory Specialist Stands Against Zydus and Sun Pharma\">Lupin Share Price: 18.9% CAGR in 3 Years as the Respiratory Specialist Stands Against Zydus and Sun Pharma<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#How_Much_Has_the_Lupin_Share_Price_Returned_in_3_Years\" title=\"How Much Has the Lupin Share Price Returned in 3 Years?\">How Much Has the Lupin Share Price Returned in 3 Years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Lupin_vs_Zydus_Lifesciences_and_Sun_Pharmaceutical_Industries_3-Year_CAGR_Compared\" title=\"Lupin vs Zydus Lifesciences and Sun Pharmaceutical Industries: 3-Year CAGR Compared\">Lupin vs Zydus Lifesciences and Sun Pharmaceutical Industries: 3-Year CAGR Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Valuation_and_Quality_Compared\" title=\"Valuation and Quality Compared\">Valuation and Quality Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#What_Is_Driving_the_Lupin_Stock\" title=\"What Is Driving the Lupin Stock?\">What Is Driving the Lupin Stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#How_the_Established_Players_Stack_Up\" title=\"How the Established Players Stack Up\">How the Established Players Stack Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#What_Should_Investors_Track_Next\" title=\"What Should Investors Track Next?\">What Should Investors Track Next?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#How_to_Compare_Pharma_Stocks_Yourself\" title=\"How to Compare Pharma Stocks Yourself\">How to Compare Pharma Stocks Yourself<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#A_Pharma_Name_With_the_Highest_ROE_and_the_Lowest_PE_in_the_Group\" title=\"A Pharma Name With the Highest ROE and the Lowest P\/E in the Group\">A Pharma Name With the Highest ROE and the Lowest P\/E in the Group<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#What_is_the_Lupin_share_price_today\" title=\"What is the Lupin share price today?\">What is the Lupin share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#What_is_the_3-year_CAGR_of_the_Lupin_stock\" title=\"What is the 3-year CAGR of the Lupin stock?\">What is the 3-year CAGR of the Lupin stock?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Is_Lupin_better_than_Sun_Pharma\" title=\"Is Lupin better than Sun Pharma?\">Is Lupin better than Sun Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#What_does_Lupin_do\" title=\"What does Lupin do?\">What does Lupin do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Is_the_Lupin_stock_debt_free\" title=\"Is the Lupin stock debt free?\">Is the Lupin stock debt free?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Is_Lupin_expensive_compared_with_the_industry\" title=\"Is Lupin expensive compared with the industry?\">Is Lupin expensive compared with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#Which_pharma_stock_gave_the_highest_return_in_3_years\" title=\"Which pharma stock gave the highest return in 3 years?\">Which pharma stock gave the highest return in 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/lupin-share-price-3-year-cagr-vs-pharma-peers-zydus-lifesciences-sun-pharma\/#How_do_I_calculate_CAGR_for_a_stock\" title=\"How do I calculate CAGR for a stock?\">How do I calculate CAGR for a stock?<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h1><span class=\"ez-toc-section\" id=\"Lupin_Share_Price_189_CAGR_in_3_Years_as_the_Respiratory_Specialist_Stands_Against_Zydus_and_Sun_Pharma\"><\/span><strong>Lupin Share Price: 18.9% CAGR in 3 Years as the Respiratory Specialist Stands Against Zydus and Sun Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h1>\n<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Lupin previous close Rs 2,025. 3-year CAGR 18.9%. Up 1.7x since 9 Nov 2023. ROE 21.65%. Market cap Rs 92,007 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Lupin share price<\/strong> closed at Rs 2,025 on 9 November 2026, a compounded annual return of 18.9% over three years. That compares with Zydus Lifesciences at 25.7% and Sun Pharmaceutical Industries at 17.4%. The company has a market cap of Rs 92,007 crore and a P\/E of 17.62 against an industry P\/E of 40.13.<\/p>\n<\/p><\/div>\n<p>The <strong>Lupin share price<\/strong> has delivered a healthy return over three years, and it has done so while keeping one of the lowest P\/E ratios among large Indian drug makers. Lupin, based in Mumbai, is known for respiratory medicines, anti-infectives and a wide generic portfolio sold in India, the United States and other markets.<\/p>\n<p>This article compares that run with Zydus Lifesciences and Sun Pharmaceutical Industries. We calculate the three-year CAGR for all three and set the results beside market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=lupin-share-price\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_the_Lupin_Share_Price_Returned_in_3_Years\"><\/span><strong>How Much Has the Lupin Share Price Returned in 3 Years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Lupin stock closed at Rs 1,204.55 on 9 November 2023 and at Rs 2,025.00 on 9 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.68 lakh, which is a CAGR of 18.9%. This is a price return and leaves out dividends.<\/p>\n<p>CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Lupin can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.<\/p>\n<p>The <strong>Lupin share price<\/strong> has also been supported by better margins in the United States generics business and by steady growth in its Indian branded portfolio.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Lupin_vs_Zydus_Lifesciences_and_Sun_Pharmaceutical_Industries_3-Year_CAGR_Compared\"><\/span><strong>Lupin vs Zydus Lifesciences and Sun Pharmaceutical Industries: 3-Year CAGR Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table ranks the companies by three-year CAGR. Prices on 9 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 9 November 2026.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Close on 9 Nov 2023<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Previous close (9 Nov 2026)<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Price multiple<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">3-year CAGR<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 612.45<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,215.90<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">2.0x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">25.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Lupin<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,204.55<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 2,025.00<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.7x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">18.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Sun Pharmaceutical Industries<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,176.20<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,904.50<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">1.6x<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.4%<\/td>\n<\/tr>\n<\/table>\n<p>The Lupin stock ranks second of the three at 18.9%. It sits ahead of Sun Pharmaceutical Industries (17.4%). The company ahead is Zydus Lifesciences (25.7%). Zydus Lifesciences leads the group, followed by Lupin and then Sun Pharma. Sun Pharma is by far the largest of the three by market cap, while Lupin is the smallest and carries the highest ROE.<\/p>\n<p>Look at the <strong>Lupin share price<\/strong> alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_and_Quality_Compared\"><\/span><strong>Valuation and Quality Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:14px 0;\">\n<tr>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Company<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Market cap<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #bbb;padding:6px 10px;background:#EBF3FB;text-align:left;\">Debt to equity<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharmaceutical Industries<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 4,57,073 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">41.60<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">13.79%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.04<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Zydus Lifesciences<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 1,21,002 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">28.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">15.10%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.50<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\"><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">Rs 92,007 crore<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">17.62<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">40.13<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">21.65%<\/td>\n<td style=\"border:1px solid #bbb;padding:6px 10px;\">0.26<\/td>\n<\/tr>\n<\/table>\n<p>By market cap, Sun Pharmaceutical Industries is the largest of the group at Rs 4,57,073 crore, while the Lupin stock stands at Rs 92,007 crore, about 20% of that size. On earnings, Lupin shares trade at a P\/E of 17.62 against an industry P\/E of 40.13, a discount of about 56% to the sector, which leaves room if earnings keep growing. Peer multiples are Zydus Lifesciences at 28.13 and Sun Pharmaceutical Industries at 41.60.<\/p>\n<p>Return on equity is 21.65% for the Lupin stock, which ranks first among the three, and debt to equity stands at 0.26. Trailing EPS is Rs 114.18. Drug makers are valued on the strength of their product baskets and approvals, so the P\/E should be read together with return on equity and the pace of earnings growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Driving_the_Lupin_Stock\"><\/span><strong>What Is Driving the Lupin Stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lupin earns revenue from branded medicines in India, generic products in the United States and sales in Europe, South Africa and other regions. It holds a strong position in respiratory and cardiac therapies, which are recurring prescription categories.<\/p>\n<p>The company has been adding complex generics and inhalation products, which face fewer competitors than plain tablets. Better plant compliance and cost control have helped profitability in recent periods.<\/p>\n<p>Followers of the <strong>Lupin share price<\/strong> usually track launches in the United States, growth of the India business, regulatory inspections at plants and progress in complex products.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_the_Established_Players_Stack_Up\"><\/span><strong>How the Established Players Stack Up<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus Lifesciences is an Ahmedabad-based drug maker with generic, specialty and vaccine businesses in India and abroad. It compounded at 25.7% a year, on a market cap of Rs 1,21,002 crore and an ROE of 15.10%.<\/p>\n<p>Sun Pharmaceutical Industries is a Mumbai-based company and the largest drug maker in India by sales, with branded, generic and specialty businesses. It compounded at 17.4% a year, on a market cap of Rs 4,57,073 crore and an ROE of 13.79%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Track_Next\"><\/span><strong>What Should Investors Track Next?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three things are worth watching on the <strong>Lupin share price<\/strong>. First, the timing of new launches in the United States. Second, the growth of the India branded business. Third, margins as complex products scale up.<\/p>\n<p>At a P\/E of 18, the stock trades well below the industry P\/E of 40, and its debt to equity of 0.26 is low. US pricing can shift from quarter to quarter, so size any position with that in mind.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals of pharma stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Compare_Pharma_Stocks_Yourself\"><\/span><strong>How to Compare Pharma Stocks Yourself<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>You can repeat this exercise for any pair of stocks, including the Lupin stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P\/E against the industry P\/E, ROE and debt to equity. Benchmark the result against the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> as well, so you know whether the stock beat the broader market.<\/p>\n<p>A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the <strong>Lupin share price<\/strong>, the same four checks give a more complete picture than price alone.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the <strong>Lupin share price<\/strong> and compare pharma stocks live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"A_Pharma_Name_With_the_Highest_ROE_and_the_Lowest_PE_in_the_Group\"><\/span><strong>A Pharma Name With the Highest ROE and the Lowest P\/E in the Group<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Lupin share price<\/strong> compounded at 18.9% a year over three years, ahead of Sun Pharma at 17.4% and behind Zydus Lifesciences at 25.7%. Its ROE of 21.65% is the highest of the three and its P\/E of 17.62 is the lowest.<\/p>\n<p>Zydus brings the faster return, while Sun Pharma brings scale and a specialty portfolio. The choice depends on which business mix you prefer.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Lupin_share_price_today\"><\/span><strong>What is the Lupin share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin closed at Rs 2,025 on 9 November 2026, according to NSE data. It has a market cap of Rs 92,007 crore and a P\/E of 17.62. Check live quotes before acting, as prices change every trading day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_3-year_CAGR_of_the_Lupin_stock\"><\/span><strong>What is the 3-year CAGR of the Lupin stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin delivered a price CAGR of 18.9% over three years, moving from Rs 1,204.55 on 9 November 2023 to Rs 2,025.00 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Lupin_better_than_Sun_Pharma\"><\/span><strong>Is Lupin better than Sun Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin delivered a higher three-year CAGR at 18.9% than Sun Pharma at 17.4%. Sun Pharma is far larger by market cap at Rs 4,57,073 crore against Rs 92,007 crore, while Lupin has a higher ROE at 21.65% against 13.79% and a lower P\/E of 17.62 against 41.60. The better choice depends on your view of each business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Lupin_do\"><\/span><strong>What does Lupin do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin is a Mumbai-based pharmaceutical company with strength in respiratory, cardiac and anti-infective medicines and a large export business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Lupin_stock_debt_free\"><\/span><strong>Is the Lupin stock debt free?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio of the Lupin stock is 0.26 and its return on equity is 21.65%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Lupin_expensive_compared_with_the_industry\"><\/span><strong>Is Lupin expensive compared with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin trades at a P\/E of 17.62 against an industry P\/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stock_gave_the_highest_return_in_3_years\"><\/span><strong>Which pharma stock gave the highest return in 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among the companies compared here, Zydus Lifesciences delivered the highest three-year CAGR at 25.7%, followed by Lupin at 18.9%. Past returns do not guarantee future performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_do_I_calculate_CAGR_for_a_stock\"><\/span><strong>How do I calculate CAGR for a stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Lupin share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin closed at Rs 2,025 on 9 November 2026, according to NSE data. It has a market cap of Rs 92,007 crore and a P\/E of 17.62. Check live quotes before acting, as prices change every trading day.\"}},{\"@type\":\"Question\",\"name\":\"What is the 3-year CAGR of the Lupin stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin delivered a price CAGR of 18.9% over three years, moving from Rs 1,204.55 on 9 November 2023 to Rs 2,025.00 on 9 November 2026. The figure excludes dividends and uses adjusted closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Is Lupin better than Sun Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin delivered a higher three-year CAGR at 18.9% than Sun Pharma at 17.4%. Sun Pharma is far larger by market cap at Rs 4,57,073 crore against Rs 92,007 crore, while Lupin has a higher ROE at 21.65% against 13.79% and a lower P\/E of 17.62 against 41.60. The better choice depends on your view of each business.\"}},{\"@type\":\"Question\",\"name\":\"What does Lupin do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin is a Mumbai-based pharmaceutical company with strength in respiratory, cardiac and anti-infective medicines and a large export business.\"}},{\"@type\":\"Question\",\"name\":\"Is the Lupin stock debt free?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio of the Lupin stock is 0.26 and its return on equity is 21.65%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.\"}},{\"@type\":\"Question\",\"name\":\"Is Lupin expensive compared with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin trades at a P\/E of 17.62 against an industry P\/E of 40.13. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stock gave the highest return in 3 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among the companies compared here, Zydus Lifesciences delivered the highest three-year CAGR at 25.7%, followed by Lupin at 18.9%. Past returns do not guarantee future performance.\"}},{\"@type\":\"Question\",\"name\":\"How do I calculate CAGR for a stock?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lupin share price compounded at 18.9% a year over 3 years. See how it compares with Zydus Lifesciences and Sun Pharma on returns, valuation and ROE.<\/p>\n","protected":false},"author":34,"featured_media":343535,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3389,21956,21955,21931],"class_list":["post-343536","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-lupin-share-price","tag-lupin-stock","tag-lupin-vs-sun-pharma","tag-pharma-stocks-india-3-year-return"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["343535"],"rank_math_title":["Lupin Share Price: 18.9% CAGR vs Zydus, Sun Pharma"],"rank_math_description":["Lupin share price compounded at 18.9% a year over 3 years. See how it compares with Zydus Lifesciences and Sun Pharma on returns, valuation and ROE."],"rank_math_focus_keyword":["Lupin share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/lupin-share-price-18-9-cagr-in-3-years-as-the-respiratory-specialist-stands.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/343536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=343536"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/343536\/revisions"}],"predecessor-version":[{"id":343537,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/343536\/revisions\/343537"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/343535"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=343536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=343536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=343536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}